Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide - Fig 1

<p>FTIR of pure PTH (1a) and physical mixture of PTH, Chitosan, Inhalable grade lactose (1b).</p

Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide

<div><p>Prothionamide (PTH), a second line antitubercular drug is used to administer in conventional oral route. However, its unpredictable absorption and frequent administration limit its use. An alternate approach was thought of administering PTH through pulmonary route in a form of nanoparticles, which can sustain the release for several hours in lungs. Chitosan, a bio-degradable polymer was used to coat PTH and further freeze dried to prepare dry powder inhaler (DPI) with aerodynamic particle size of 1.76μm. <i>In vitro</i> release study showed initial burst release followed by sustained release up to 96.91% in 24h. <i>In vitro</i> release further correlated with <i>in vivo</i> study. Prepared DPI maintained the PTH concentration above MIC for more than 12h after single dose administration and increased the PTH residency in the lungs tissue more than 24h. Animal study also revealed the reduction of dose in pulmonary administration, which will improve the management of tuberculosis.</p></div

Bio-distribution of PTH in free and nanoparticles form.

<p>Bio-distribution of PTH in free and nanoparticles form.</p